Humatica advises Baird Capital on their investment in Azzur Group

Humatica, the leading private equity specialist advisor for portfolio company organisational effectiveness, has advised  Baird Capital’s private equity team on its investment in Azzur Group. Azzur is a provider of professional services to FDA regulated industries, helping life science customers navigate the regulatory complexities of product development, manufacturing, and commercialization.

Azzur Group operates three lines of business: Consulting, LabServices, and the recently launched Cleanrooms on Demand (COD). All of Azzur Group’s business lines have experienced strong growth for the past years while sporting robust margins. Baird’s investment will support the growth targets of Azzur Group’s various service lines, and especially on the COD’s rapid build-out.

Humatica was engaged by Baird Capital to provide Organisational Due Diligence advice for this transaction.

Marcel Bättig, Humatica Partner, commented:

“The transaction demonstrates Humatica’s capability to perform an organizational due diligence fully virtually, while building strong rapport with the management team of the company. It also shows that partnering with both the fund and the company maximizes deal value and mutual trust. We wish Azzur Group’s management team continued success and are proud to have assisted Baird Capital on this transaction.”

Brett Tucker, Baird Capital Partner, added:

“Baird Capital has a history of investing in pharma services businesses, and we look forward to bringing our resources, relationships, and experiences to support Azzur’s future growth. We are excited to partner with Azzur and its strong leadership team to help them build on their past successes.”

The Humatica team was led by Marcel Bättig, Partner.

To download the news release in PDF format, klicken Sie hier.